Literature DB >> 20187242

Examining Braak's hypothesis by imaging Parkinson's disease.

David J Brooks1.   

Abstract

In this review, in vivo patterns of structural, metabolic, and neurotransmitter binding changes revealed by imaging in both symptomatic Parkinson's disease (PD) and at-risk subjects are compared with those predicted at different Braak stages. It is concluded that the dysfunction revealed by imaging in PD is only partially in line with the sequential ascending topography of Lewy body pathology reported by Braak, suggesting that neurons in different brain regions are likely to be selectively vulnerable to the presence of intracellular synuclein aggregates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20187242     DOI: 10.1002/mds.22720

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

Review 1.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 2.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

3.  Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson's disease.

Authors:  Aron S Buchman; Sukriti Nag; Sue E Leurgans; Jared Miller; Veronique G J M VanderHorst; David A Bennett; Julie A Schneider
Journal:  Brain Pathol       Date:  2017-10-27       Impact factor: 6.508

Review 4.  Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Authors:  Thomas Müller; Bernhard Klaus Mueller; Peter Riederer
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

Review 5.  Inflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link?

Authors:  Carla M Lema Tomé; Trevor Tyson; Nolwen L Rey; Stefan Grathwohl; Markus Britschgi; Patrik Brundin
Journal:  Mol Neurobiol       Date:  2012-04-29       Impact factor: 5.590

6.  Dopamine and α-synuclein dysfunction in Smad3 null mice.

Authors:  Silvia Tapia-González; Rosa M Giráldez-Pérez; M Isabel Cuartero; M José Casarejos; M Ángeles Mena; Xiao-Fan Wang; Amelia Sánchez-Capelo
Journal:  Mol Neurodegener       Date:  2011-10-13       Impact factor: 14.195

7.  Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease.

Authors:  Oliver Cooper; Hyemyung Seo; Shaida Andrabi; Cristina Guardia-Laguarta; John Graziotto; Maria Sundberg; Jesse R McLean; Luis Carrillo-Reid; Zhong Xie; Teresia Osborn; Gunnar Hargus; Michela Deleidi; Tristan Lawson; Helle Bogetofte; Eduardo Perez-Torres; Lorraine Clark; Carol Moskowitz; Joseph Mazzulli; Li Chen; Laura Volpicelli-Daley; Norma Romero; Houbo Jiang; Ryan J Uitti; Zhigao Huang; Grzegorz Opala; Leslie A Scarffe; Valina L Dawson; Christine Klein; Jian Feng; Owen A Ross; John Q Trojanowski; Virginia M-Y Lee; Karen Marder; D James Surmeier; Zbigniew K Wszolek; Serge Przedborski; Dimitri Krainc; Ted M Dawson; Ole Isacson
Journal:  Sci Transl Med       Date:  2012-07-04       Impact factor: 19.319

Review 8.  Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease.

Authors:  Jelena Osmanovic Barilar; Ana Knezovic; Ana Babic Perhoc; Jan Homolak; Peter Riederer; Melita Salkovic-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2020-02-06       Impact factor: 3.575

9.  Simulating the progression of brain structural alterations in Parkinson's disease.

Authors:  Chang-Hyun Park; Na-Young Shin; Sang-Won Yoo; Haeseok Seo; Uicheul Yoon; Ji-Yeon Yoo; Kookjin Ahn; Joong-Seok Kim
Journal:  NPJ Parkinsons Dis       Date:  2022-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.